PNGM — Er Therapeutics Share Price
Last trade - 00:00- $0.00m
- $0.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Nov | Unit | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Er Therapeutics, Inc., formerly Pengram Corporation (Pengram), is an exploration stage company. The Company has not realized any revenues from its planned operations. The Company is engaged in acquiring exploration and development of natural resource properties. The Company has not commenced business operations. The Company has interests in Clisbako claims and Eureka claims. The Company has 100% interest in a group of ten mineral claims, collectively known as the Clisbako claims, which are located in the Cariboo Mining Division of British Columbia, Canada. The Company also has 100% interest in a series of mineral claims referred to as the CPG Project, Fish Claims and The Golden Snow Property, collectively known as the Eureka claims, which are situated in the Eureka County, Esmeralda County and Mineral County, Nevada.
Directors
- Last Annual
- November 30th, 2010
- Last Interim
- August 31st, 2012
- Incorporated
- April 28th, 2006
- Public Since
- August 10th, 2007
- No. of Shareholders
- 28
- Sector
- Metals & Mining
- Industry
- Basic Materials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 58,264,344
- Address
- 1200 Dupont St Ste 23, BELLINGHAM, 98225-3100
- Web
- Phone
- +1 3602553436
- Auditors
- Davidson & Co LLP
Similar to PNGM
0187279 BC
Pink Sheets on Nasdaq
Aerofoam Metals
Pink Sheets on Nasdaq
Affinity Gold
Pink Sheets on Nasdaq
AIM Energy
Pink Sheets on Nasdaq
Aladdin Separation Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 22:35 UTC, shares in Er Therapeutics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Er Therapeutics last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Er Therapeutics share price has underperformed the S&P500 Index by -6.57% over the past year.
There is no consensus recommendation for this security.
Find out moreEr Therapeutics does not currently pay a dividend.
Er Therapeutics does not currently pay a dividend.
Er Therapeutics does not currently pay a dividend.
To buy shares in Er Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Er Therapeutics had a market capitalisation of $0.00m.
Here are the trading details for Er Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PNGM
Based on an overall assessment of its quality, value and momentum Er Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Er Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Er Therapeutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Er Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Er Therapeutics' management team is headed by:
- Richard Donaldson - CEO
- Howard Metzler - DRC